Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
New Insights in Respiratory Diseases
share announcement

New Insights in Respiratory Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 4304

Special Issue Editor

Dr. Diego Bagnasco

E-Mail Website
Guest Editor
1. Respiratory and Allergy Clinic, Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy
2. IRCCS Policlinico San Martino, 16132 Genoa, Italy
Interests: asthma; severe asthma; lung disease; lung physiopathology; T2 inflammation; rhinosinusitis; nasal polyps
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This compilation of articles under the Special Issue titled "New Insights in Respiratory Diseases" will serve as a vital contribution to the scientific community by advancing our understanding of respiratory pathophysiology and therapeutic intervention strategies, particularly in asthma, COPD, and bronchiectasis. Contributions to this collection of valuable work will allow researchers and clinicians to share novel findings and critical analyses that challenge conventional paradigms and highlight emerging trends in the diagnosis, treatment, and management of respiratory disorders. Detailed scientific manuscripts foster interdisciplinary collaboration and cultivate a robust framework for the integration of basic science, clinical data, and translational research. High-quality manuscripts play an essential role in elucidating the complex mechanisms underlying respiratory conditions, from chronic obstructive pulmonary disease to bronchiectasis. By disseminating data-driven evidence and systematic reviews, these manuscripts contribute to the optimization of patient care and the refinement of clinical guidelines. Each contribution not only documents current advancements but also identifies knowledge gaps that warrant further investigation, thereby stimulating future research directions. Furthermore, authors are instrumental in providing critical insights into the molecular, cellular, and genetic determinants of respiratory diseases. Their work supports the development of innovative diagnostic tools and personalized therapies that address patient-specific needs. The peer-reviewed nature of these articles ensures that findings meet rigorous scientific standards, thereby enhancing the credibility of the conclusions drawn. Ultimately, the aggregation of well-researched articles within this collection empowers healthcare professionals to make informed decisions, encourages the adaptation of best practices in clinical settings, and drives progress towards improved respiratory health outcomes.

Dr. Diego Bagnasco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • COPD
  • bronchiectasis
  • genetic
  • therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1777 KB  
Article
Assessing the Heterogeneous Treatment Effects of Glucocorticoids in Infants and Toddlers with Severe Pneumonia
by Zhoumeng Ying, Haiyan Ge, Wei Han, Ge Hu, Zhenchen Zhu, Jinhua Wang, Lan Song, Dong Qu and Zhengyu Jin
Biomedicines 2025, 13(10), 2333; https://doi.org/10.3390/biomedicines13102333 - 24 Sep 2025
Viewed by 527
Abstract
Background: Community-acquired pneumonia (CAP) is a leading cause of pediatric hospitalizations and a risk factor for chronic respiratory conditions. Glucocorticoids (GCs) are used as adjunctive therapy to reduce inflammation, but their efficacy in infants and toddlers remains unclear. Method: A retrospective [...] Read more.
Background: Community-acquired pneumonia (CAP) is a leading cause of pediatric hospitalizations and a risk factor for chronic respiratory conditions. Glucocorticoids (GCs) are used as adjunctive therapy to reduce inflammation, but their efficacy in infants and toddlers remains unclear. Method: A retrospective study of 1116 infants and toddlers with severe CAP was conducted, using causal forest to estimate individual treatment effects (ITEs), with the duration of intensive care unit (ICU) stay as the outcome. Patients were stratified based on ITEs to investigate the heterogeneous treatment effect (HTE) and identify responders. Generalized linear models validated the HTE across subclasses, followed by comparative analyses to characterize responders. Variable importance was assessed using the causal model, and Shapley additive explanations (SHAP) quantified each variable’s contribution to the ITE. Analysis was also performed in mechanically ventilated patients (MV group). Results: GCs demonstrated significant HTE. Older patients and those with elevated inflammation markers showed better responses, whereas no such benefit was observed in respiratory syncytial virus-infected patients. These subgroups experienced shorter ICU stays both in the whole cohort (β = −0.16, p < 0.001) and MV group (β = −0.34, p < 0.001), and shorter ventilation duration was observed in the MV group (β = −0.35, p < 0.001). Age and the anion gap were key predictors of ITEs. SHAP analysis revealed a positive correlation between age and GC effectiveness. Conclusions: Significant heterogeneity in GC treatment effects exists among infants and toddlers with severe CAP, highlighting the need for optimization of GC use in this population. Full article
(This article belongs to the Special Issue New Insights in Respiratory Diseases)
►▼ Show Figures

Graphical abstract

13 pages, 459 KB  
Article
The Impact of Pulmonary Hypertension on Hospitalization Risk in Adults with Respiratory Syncytial Virus Infection
by Mayuri Mudgal, Aseem Rai Bhatnagar, Aneesh Kumar Vasudevan, Ajeetha Priya Gajendiran, Venkatesh Gondhi, Swetha Balaji, Shanjai Krishnan Murugan and Kulothungan Gunasekaran
Biomedicines 2025, 13(9), 2272; https://doi.org/10.3390/biomedicines13092272 - 16 Sep 2025
Viewed by 633
Abstract
Background/Objectives: Respiratory syncytial virus (RSV) infection can lead to significant complications, particularly among those with underlying cardiovascular and pulmonary complications. Patients with pulmonary hypertension (PH) are susceptible to clinical deterioration triggered by respiratory infections due to their limited cardiopulmonary reserve. This study [...] Read more.
Background/Objectives: Respiratory syncytial virus (RSV) infection can lead to significant complications, particularly among those with underlying cardiovascular and pulmonary complications. Patients with pulmonary hypertension (PH) are susceptible to clinical deterioration triggered by respiratory infections due to their limited cardiopulmonary reserve. This study aimed to assess the risk of hospitalization in RSV-infected adults with and without PH. Methods: We conducted a retrospective cohort study using the research network TriNetX to assess the risk of hospitalization in a cohort of patients with RSV infection, comparing those with and without PH. Propensity score matching was performed for demographic variables and RSV risk factors between the two cohorts. The risk of hospitalization was expressed as an adjusted odds ratio (aOR) with a 95% confidence interval (CI). Results: There were 193,256 patients in the RSV with PH cohort and 2,843,714 in the RSV without PH cohort (all aged >18 years). The mean age of the RSV with PH cohort was 68.2 ± 15.3 years, 50.6% were females, 64% were white, and 64.2% were group 2 PH. The RSV with PH cohort was at an increased risk of hospitalization (aOR 1.89, 95% CI 1.87–1.92, p-value 0.02). There was a significant risk (aOR 1.29, 95% CI 1.27–1.32) for the composite outcome of hospitalization-related complications between the two cohorts. Comorbid conditions (diabetes, cardiovascular disease, chronic lung disease, and chronic kidney disease) increased the risk of hospitalization in the RSV with PH group, with the biggest effect noted with underlying cardiovascular disease. Similarly, those with group 2 PH had a higher risk of hospitalization compared to the other PH groups. Remarkably, all PH groups demonstrated increased hospitalization risk compared to the RSV without PH cohort. Conclusions: We found that patients >18 years of age with PH and RSV infection were at an increased risk of hospitalization, with subsequently higher rates of RSV-infection-related complications. All PH groups had a higher hospitalization risk compared to the RSV without PH cohort, likely denoting PH as an independent risk factor for worse RSV-infection-related outcomes. RSV vaccination, therefore, may benefit all age groups of patients with PH. Full article
(This article belongs to the Special Issue New Insights in Respiratory Diseases)
►▼ Show Figures

Figure 1

19 pages, 2154 KB  
Article
Association of LPCAT1*rs9728 Variant with Reduced Susceptibility to Neonatal Respiratory Distress Syndrome
by Shimaa Dorgham, Sohier Yahia, Doaa Shahin, Ahmad M. Eita, Eman A. Toraih and Rami M. Elshazli
Biomedicines 2025, 13(9), 2237; https://doi.org/10.3390/biomedicines13092237 - 11 Sep 2025
Viewed by 789
Abstract
Background/Objectives: Neonatal respiratory distress syndrome (NRDS) is a heterogenous respiratory illness that mainly affects preterm neonates. It is characterized by insufficient production of pulmonary surfactant and impaired lung compliance. The lysophosphatidylcholine acyltransferase 1 (LPCAT1) enzyme has a crucial function in lipid remodeling [...] Read more.
Background/Objectives: Neonatal respiratory distress syndrome (NRDS) is a heterogenous respiratory illness that mainly affects preterm neonates. It is characterized by insufficient production of pulmonary surfactant and impaired lung compliance. The lysophosphatidylcholine acyltransferase 1 (LPCAT1) enzyme has a crucial function in lipid remodeling through the conversion of lysophosphatidylcholine to phosphatidylcholine, the major component of pulmonary surfactant. In this research, we aimed to investigate the association of the LPCAT1*rs9728 variant with NRDS susceptibility using hereditary analysis and bioinformatic approaches. Methods: The LPCAT1 (rs9728; c.*1668T>C) variant was characterized among 100 preterm neonates with RDS and 100 non-RDS neonates utilizing the TaqMan SNP genotyping assay. Logistic regression analysis was performed to identify the risk factors of respiratory distress syndrome. The functional mechanism of the LPCAT1 gene was elucidated using bioinformatic approaches. Results: The LPCAT1*rs9728 C/C genotype was significantly associated with a 78% reduced risk of NRDS (OR = 0.22, p = 0.027), although the minor C allele did not attain a significant finding (OR = 0.83, p = 0.416). Apgar score and Silverman–Andersen respiratory severity score (RSS) were statistically significant with prematurity classes (p < 0.05). Additionally, gestational age and birth weight were considered independent risk factors in the progression of RDS among preterm neonates. Conclusions: This research exhibited a significant difference between the LPCAT1 (rs9728; c.*1668T>C) variant and reduced risk against the development of RDS among preterm neonates. The rs9728*C/C genotype revealed a significant association with decreased risk of NRDS compared to non-RDS neonates. Full article
(This article belongs to the Special Issue New Insights in Respiratory Diseases)
►▼ Show Figures

Figure 1

22 pages, 9750 KB  
Article
SIK2 Drives Pulmonary Fibrosis by Enhancing Fibroblast Glycolysis and Activation
by Jianhan He, Ruihan Dong, Huihui Yue, Fengqin Zhang, Xinran Dou, Xuan Li, Hui Li and Huilan Zhang
Biomedicines 2025, 13(8), 1919; https://doi.org/10.3390/biomedicines13081919 - 6 Aug 2025
Viewed by 1016
Abstract
Background: Pulmonary fibrosis (PF), the end-stage manifestation of interstitial lung disease, is defined by excessive extracellular matrix deposition and alveolar destruction. Activated fibroblasts, the primary matrix producers, rely heavily on dysregulated glucose metabolism for their activation. While Salt Inducible Kinase 2 (SIK2) regulates [...] Read more.
Background: Pulmonary fibrosis (PF), the end-stage manifestation of interstitial lung disease, is defined by excessive extracellular matrix deposition and alveolar destruction. Activated fibroblasts, the primary matrix producers, rely heavily on dysregulated glucose metabolism for their activation. While Salt Inducible Kinase 2 (SIK2) regulates glycolytic pathways in oncogenesis, its specific contributions to fibroblast activation and therapeutic potential in PF pathogenesis remain undefined. This study elucidates the functional role of SIK2 in PF and assesses its viability as a therapeutic target. Methods: SIK2 expression/localization in fibrosis was assessed by Western blot and immunofluorescence. Fibroblast-specific Sik2 KO mice evaluated effects on bleomycin-induced fibrosis. SIK2’s role in fibroblast activation and glucose metabolism impact (enzyme expression, metabolism assays, metabolites) were tested. SIK2 inhibitors were screened and evaluated therapeutically in fibrosis models. Results: It demonstrated significant SIK2 upregulation, specifically within activated fibroblasts of fibrotic lungs from both PF patients and murine models. Functional assays demonstrated that SIK2 is crucial for fibroblast activation, proliferation, and migration. Mechanistically, SIK2 enhances fibroblast glucose metabolism by increasing the expression of glycolysis-related enzymes. Additionally, this study demonstrated that the SIK2 inhibitor YKL06-061 effectively inhibited PF in both bleomycin and FITC-induced PF mouse models with the preliminary safety profile. Furthermore, we identified a novel therapeutic application for the clinically approved drug fostamatinib, demonstrating it inhibits fibroblast activation via SIK2 targeting and alleviates PF in mice. Conclusions: Our findings highlight SIK2 as a promising therapeutic target and provide compelling preclinical evidence for two distinct anti-fibrotic strategies with significant potential for future PF treatment. Full article
(This article belongs to the Special Issue New Insights in Respiratory Diseases)
►▼ Show Figures

Figure 1

12 pages, 676 KB  
Article
Challenges Pertaining to the Optimization of Therapy and the Management of Asthma—Results from the 2023 EU-LAMA Survey
by Michał Panek, Robab Breyer-Kohansal, Paschalis Steiropoulos, Peter Kopač, Monika Knopczyk, Tomasz Dębowski, Christer Janson and Maciej Kupczyk
Biomedicines 2025, 13(8), 1877; https://doi.org/10.3390/biomedicines13081877 - 1 Aug 2025
Viewed by 625
Abstract
Background: Treatment compliant with the Global Initiative for Asthma (GINA) can promote more effective disease control. Single-inhaler triple therapy (SITT) is one method that is used to optimize therapy in this context, but TRIPLE therapy is still employed by physicians to a limited [...] Read more.
Background: Treatment compliant with the Global Initiative for Asthma (GINA) can promote more effective disease control. Single-inhaler triple therapy (SITT) is one method that is used to optimize therapy in this context, but TRIPLE therapy is still employed by physicians to a limited extent. Objective: This study aimed to describe the factors influencing challenges in optimizing asthma therapy. Methods: A 19-question survey, created via the CATI system, was distributed among pulmonologists, allergologists, general practitioners, and internal medicine specialists in Poland, Greece, Sweden, Slovenia, and Austria. Results: Statistically significant percentage differences in the use of TRIPLE therapy in the context of asthma management were observed among countries as well as between pulmonologists, allergists, and other specialists. Overuse of oral corticosteroids (OCSs) to treat nonsevere and severe asthma in the absence of an approach that focuses on optimizing inhalation therapy among asthma patients receiving TRIPLE therapy was observed in different countries as well as among physicians with different specialties. Twenty elements associated with the challenges involved in diagnosing and managing difficult-to-treat and severe asthma were identified. Six clinical categories for the optimization of asthma therapy via SITT were highlighted. The degree of therapeutic underestimation observed among severe asthma patients was assessed by comparing actual treatment with the recommendations of the GINA 2023 guidelines. Conclusions: Physicians of various specialties in Europe are subject to therapeutic inertia in terms of their compliance with the GINA 2023 guidelines. Full article
(This article belongs to the Special Issue New Insights in Respiratory Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop